LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
LifeStance Health Group director Eric Shuey reported an indirect share sale through a family trust. On this Form 4, the Eric Shuey Gift Trust completed an open-market sale of 243,362 shares of LifeStance common stock at a price of $8.02 per share. Following the transaction, the trust held 867,562 shares indirectly, while Shuey also reported 93,982 shares held directly. The filing notes that Shuey disclaims beneficial ownership of the trust-held securities except to the extent of his pecuniary interest.
LifeStance Health Group, Inc. director Darren M. Black reported an indirect open-market sale of 5,899,661 shares of Common Stock at $8.02 per share through Summit Partners–affiliated investment entities. After these transactions, the filing shows these entities holding 23,310,115 shares in total. The shares are held across several Summit funds, and the footnotes state that Summit Partners, L.P., via an investment committee that includes Black, has voting and dispositive power while each person and fund disclaims beneficial ownership except to the extent of pecuniary interest.
LifeStance Health Group, Inc. reported that an entity affiliated with TPG completed an open-market sale of 28,281,943 shares of Common Stock at $8.02 per share. After this transaction, TPG VIII Lynnwood Holdings Aggregation, L.P. continues to hold 111,744,614 shares indirectly, with the reporting persons only deemed beneficial owners to the extent of their pecuniary interests.
LifeStance Health Group, Inc. entered into an Underwriting Agreement with J.P. Morgan Securities LLC and certain selling stockholders for an underwritten offering of 35,000,000 shares of its common stock under an existing Form S-3 registration statement.
All 35,000,000 shares are being sold by the selling stockholders, so the Company did not receive any proceeds from the offering. Separately, the Company agreed to repurchase 6,000,000 of these shares from the Underwriter at the same price the Underwriter paid the selling stockholders, and the Underwriter received no compensation on the repurchased shares.
The offering closed on May 12, 2026. The filing also notes an opinion from Ropes & Gray LLP regarding the shares and lists the underwriting agreement and related legal opinion as exhibits.
LifeStance Health Group director Robert Bessler reported open-market sales of LifeStance Health Group, Inc. common stock through entities associated with him. Shama LLC and Vitthal LLC each sold 37,500 shares at a weighted average price of $8.55 per share, in transactions ranging from $8.40 to $8.89. After these sales, Shama LLC held 1,353,746 shares and Vitthal LLC held 1,236,948 shares. Bessler also reported 57,619 shares held directly and 36,363 shares held by Alpine Glow Capital. Footnotes state that he disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.
Summit Partners and affiliated funds reported shared beneficial ownership of LifeStance Health Group common stock. Summit Partners, L.P. has 29,209,776 shares with shared voting and dispositive power, representing 7.49% of the class. The filing cites 389,783,210 shares outstanding as of February 17, 2026.
The Schedule 13G/A lists related Summit entities (including Growth Equity Fund IX‑A and IX‑B) with shared holdings of 17,886,858 and 11,168,308 shares respectively and explains the fund/committee voting structure and delegations.
LifeStance Health Group, Inc. is offering for resale 35,000,000 shares of common stock by selling stockholders; the Company is not selling any shares hereunder and will receive no proceeds from those sales. Subject to the closing of the offering, the Company intends to purchase 6,000,000 shares from the underwriter at the public offering price and retire them. The repurchase is contingent on the offering closing. Shares outstanding were 387,834,432 as of April 29, 2026. The underwriter is J.P. Morgan, the public offering price is $8.15 per share and the underwriting discount is $0.13 per share. The underwriter expects to deliver the shares on or about May 12, 2026.
35,000,000 shares of common stock are being registered for resale by identified selling stockholders of LifeStance Health Group, Inc. The Company is not selling any shares and will not receive proceeds from the selling stockholders' sales.
Subject to the offering closing, LifeStance intends to purchase 6,000,000 of the offered shares from the underwriter at the same per-share price paid by the underwriter and retire those repurchased shares. Shares outstanding were 387,834,432 as of April 29, 2026. The prospectus supplement states the Company estimates offering expenses of approximately $500,000 and quotes a last reported Nasdaq sale price of $7.36 on May 6, 2026.
LifeStance Health (LFST) filed a Form 144 reporting proposed sales of 75,000 shares of Common Stock, with an aggregate value listed as $641,580.00, dated 05/07/2026.
The filing also records recent dispositions: 5,101 shares on 04/21/2026 for $35,749.48, 7,752 shares on 04/23/2026 for $54,267.10, and 62,147 shares on 04/24/2026 for $438,074.20. The excerpt shows two prior private placement transfers dated 06/01/2017 of 37,500 shares each to Vitthal LLC and Shama LLC.
LifeStance Health Group reported strong Q1 performance, with total revenue rising 21% to $403,476, driven by higher patient service revenue from a larger clinician base and more visits. Income from operations increased to $22,284, and net income improved sharply to $14,243, or $0.04 per diluted share.
Adjusted EBITDA reached $51,110, supported by 2.5 million patient visits and 8,349 employed clinicians as of March 31, 2026. The company generated $33,109 of operating cash flow, repurchased 7,000 shares for $49,107, and ended the quarter with $194,797 in cash. Previously identified material weaknesses in internal control over financial reporting remain unresolved, so disclosure controls are still not effective.